Press releases

8 Feb 2023

FINTEPLA[®]▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

18 Jan 2023

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

9 Jan 2023

UCB's financial update

6 Jan 2023

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

23 Dec 2022

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

19 Dec 2022

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Press releases

Press releases

Search Press releases

FINTEPLA[®]▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB's financial update

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

FINTEPLA[®]▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB's financial update

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Choose a Country